1. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma 
Yago Nieto, Peter F. Thall, Junsheng Ma, Benigno C. Valdez, Sairah Ahmed, Paolo Anderlini, Uday Popat, Roy B. Jones, Elizabeth J. Shpall, Chitra Hosing, Muzaffar Qazilbash, Partow Kebriaei, Amin Alousi, Melissa Timmons, Alison Gulbis, Alan Myers, Yasuhiro Oki, Michelle Fanale, Bouthaina Dabaja, Chelsea Pinnix, Sarah Milgrom, Richard Champlin, Borje S. Andersson 
Biology of Blood and Marrow Transplantation 
Volume 24, Issue 8, Pages (August 2018)
DOI: /j.bbmt
Copyright © 2018 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Prognostic stratification of Gem/Bu/Mel patients according to PET status at HDC (A) and based on the International Prognostic Score (B).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2018 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Comparison of outcomes in the Gem/Bu/Mel and BEAM cohorts. (A) PFS (P = .05, unstratified; P = .008, stratified for PET and DFI-6). (B) OS (P = .0008, unstratified; P = .0003, stratified for PET and DFI-6).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2018 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Studies of DNA damage response in peripheral blood mononuclear cells of patients receiving Gem/Bu/Mel (n = 19). (A) Cellular changes in the level of γ-H2AX levels. (B) Representative cases of decreased PARP-1 levels.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2018 The American Society for Blood and Marrow Transplantation Terms and Conditions